Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-06-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of 31 May 2023, providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a regulatory disclosure about voting rights. The document length is 3150 characters, which is relatively short and primarily serves as an announcement of voting rights information rather than a detailed report or financial statement. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially notifies shareholders about voting rights figures used for notification thresholds. It is not an annual report, earnings release, or other financial report, nor is it a proxy solicitation or management change announcement. Therefore, the best classification is DVA with high confidence.
2023-06-01 English
Block listing Interim Review
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING SIX MONTHLY RETURN' and is provided via 'RNS Number'. It details the balance and movement of unallotted securities under various share option plans over a specific period (1 DECEMBER 2022 to 31 MAY 2023). This type of filing, which reports on the status of securities reserved for employee plans, is a specific regulatory disclosure. While it relates to share capital, it is not a general share issue (SHA) or a transaction in own shares (POS). Since it is a formal regulatory announcement distributed via RNS, and it doesn't fit the specific definitions for AGM-R, 10-K, ER, or IR, it falls best under the general regulatory announcement category, RNS, as it is a required periodic disclosure to the exchange regarding listed securities status.
2023-06-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service). The content explicitly states the purpose is to provide information regarding 'Voting rights and capital' as required by the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. It details the total number of voting rights (1,549,869,963) as of a specific date (31 May 2023). This type of mandatory, periodic disclosure regarding the total number of shares with voting rights is a standard regulatory announcement. Since it is a specific regulatory update that doesn't fit perfectly into the other defined categories (like DIRS, DIV, or SHA, which are more specific transaction types), and it is clearly a regulatory filing disseminated via RNS, the most appropriate classification is RNS, as it serves as a general regulatory announcement/disclosure.
2023-06-01 English
LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Lynparza in the US for BRCA-mutated metastatic castration-resistant prostate cancer, including clinical trial results, regulatory milestones, and company collaboration details. The document is not an annual or quarterly report, nor is it a transcript, audit, or management change announcement. It is a regulatory filing providing material information about a significant corporate event (drug approval and related financial considerations). The length and content indicate it is not a brief announcement or a report publication notice but a substantive regulatory disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-06-01 English
Lynparza approved in US for BRCAm prostate cancer
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and the date '01 June 2023', indicating it is a regulatory news service announcement. The content is a press release announcing a regulatory achievement: the US approval of Lynparza in combination with abiraterone for a specific cancer indication. It includes quotes from executives and scientific investigators, details about the clinical trial (PROpel), and notes on financial considerations (milestone payment). This format—a formal announcement of a significant corporate/regulatory event via RNS—is characteristic of a general regulatory filing or announcement, rather than a comprehensive financial report (10-K, IR) or a specific management/governance document. Since it is a formal announcement distributed via RNS that doesn't fit the more specific categories like ER, DIV, or CAP, the most appropriate classification is the general regulatory filing category.
2023-06-01 English
IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial results and drug information but does not include comprehensive financial statements or management discussion typical of annual or interim reports. The document is about a clinical trial result announcement and related drug information, not an earnings release or financial report. It is a regulatory filing submitted to the SEC to disclose material information. The length is about 14,691 characters, which is substantial but the content is primarily clinical and regulatory information rather than financial data. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-05-26 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.